P/E ratio for Lexicon Pharmaceuticals (LXRX)

P/E ratio history for Lexicon Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Eterna Therapeutics ERNA	-0.1915	-89.06%	🇺🇸 USA
Regeneron Pharmaceuticals REGN	22.0	-1,355.74%	🇺🇸 USA
Ultragenyx RARE	-4.67	166.96%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	84.9	-4,953.02%	🇺🇸 USA
Thermo Fisher Scientific TMO	35.3	-2,114.34%	🇺🇸 USA
Esperion Therapeutics ESPR	-0.8617	-50.76%	🇺🇸 USA
Illumina ILMN	-5.55	217.00%	🇺🇸 USA
Ligand Pharmaceuticals LGND	76.9	-4,494.54%	🇺🇸 USA
Aerie Pharmaceuticals AERI	-20.3	1,061.90%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.